Compare Crispr Therapeutics AG (CRSP) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Phillips 66 — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Phillips 66 trades at $201 (market cap $80.77B). The key difference: Phillips 66 is far larger — about 16.3× Crispr Therapeutics AG's market cap, and Phillips 66 pays a 2.52% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PSX | |
|---|---|---|
Market Cap | $4.97B | $80.77B |
Sector | Health | Energy |
52-Week High | $76.78 | $201.45 |
52-Week Low | $44.34 | $118.37 |
Enterprise Value | $3.32B | $102.74B |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Phillips 66 (PSX) trades at $198.29, up 5.27% with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 19.59, P/S of 0.6, and ROE of 14.75%, though revenue declined from $170B in 2022 to $132.38B in 2025. Recent earnings beats and consistent dividends of $1.27 quarterly support investor confidence amid refining margin strength.
Outlook remains positive with analyst consensus at Buy (57%) and $201.50 target, though risks include volatile oil prices, declining revenue trends, and high RSI suggesting overbought conditions. The refining sector benefits from Middle East tensions, but execution on cost control and margin stability will dictate near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
